 |
|
|
|
 |
|
|
| Article 1 to 10 out of 17 concerning Antisoma plc
|
-
Evidence of activity seen in new data from ASA404 prostate cancer trial
(18 Aug 2008)
Antisoma plc announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of ...
-
Antisoma's ASA404 programme to expand with new pivotal trial in lung cancer
(21 Jul 2008)
ATTRACT-2 study will evaluate ASA404 as second-line treatment
Antisoma plc ( announced that its Tumour-Vascular Disrupting Agent, ASA404, will enter a second pivotal phase III trial this year. The ATTRACT-2 (Anti-vascular Targeted Therapy: Researching ASA404 in Cancer Treatment-2) trial will be conducted by ...
-
Antisoma to acquire Boston-based Xanthus Pharmaceuticals
(20 May 2008)
Antisoma plc announced that it has entered into an agreement to acquire private US oncology company Xanthus Pharmaceuticals, Inc. in an all-share deal valued at GBP 26.8 million (USD 52.2 million). Simultaneously, Antisoma has executed a fundraising ...
-
Antisoma announces start of phase III lung cancer trial of ASA404
(14 Apr 2008)
Initiation triggers USD 25 million milestone payment from Novartis
Antisoma plc announced that its partner Novartis has started the pivotal phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer (NSCLC). The study, called ATTRACT-1, is designed to support applications for ...
-
Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma
(26 Feb 2008)
Antisoma plc announced the entry of AS1409 into clinical trials. A phase I trial has started in patients with renal cancer and melanoma. The trial has two parts. In the first, successive cohorts of patients will receive increasing doses of AS1409. ...
-
Antisoma starts phase II trial of AS1411 in acute myeloid leukaemia
(07 Aug 2007)
Antisoma plc announced that it has started a randomised phase II trial of AS1411 in AML (acute myeloid leukaemia). Around 70 patients will be recruited at major cancer centres in the USA.The trial tests AS1411 in patients with relapsed or refractory ...
-
Novartis-Partner Antisoma stops ASA404 ovarian cancer trial
(13 Jul 2007)
Cancer drug developer Antisoma plc announces new data from its phase II trial of ASA404 in recurrent, platinum-sensitive ovarian cancer. This trial compares patients receiving ASA404 plus chemotherapy (n=37) with patients receiving chemotherapy ...
-
Antisoma announces global agreement with Novartis for cancer drug AS1404
(20 Apr 2007)
Antisoma plc announced that it has signed an exclusive global licensing agreement with Novartis for its vascular disrupting agent AS1404 (DMXAA). Antisoma will receive near-term payments of USD 100 million. USD 75 million will be paid immediately ...
-
Dramatic response seen with Antisoma's AS1411 in renal cancer
(06 Sep 2006)
Antisoma today announced that a second late-stage renal cancer patient in its phase I trial of AS1411 has experienced major tumour shrinkage. This follows a similar case reported earlier from the same trial.The latest responder had four separate ...
-
Antisoma's AS1404 enhances effectiveness of Avastin in colon and lung cancer models
(03 Apr 2006)
A preclinical data presentation at the American Association of Cancer Research (AACR) revealed that a combination of Antisoma's AS1404 and Avastin was considerably more effective than Avastin alone at inhibiting the growth of human colon and lung ...
Additional information
Antisoma plc
London, United Kingdom
Company
|
|
|
|
|
|
Top
